Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.63 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 4/20 | 0.62 |
| ▸ | MMP1 | P03956 | 1/20 | 0.59 |
| ▸ | MMP12 | P39900 | 1/20 | 0.59 |
| ▸ | IDO1 | P14902 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.56 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | ACP3 | P15309 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | THRA | P10827 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20267723 | 0.87 | IDO1 (0.62) | PRKCAPRKCDMAOBMMP1MMP12 | |
| SCHEMBL10005902 | 0.85 | ALDH1A1 (0.58) | PRKCAPRKCDMAOBMMP1MMP12 | |
| SCHEMBL2030657 | 0.85 | PRKCA (0.58) | PRKCAPRKCDMAOBMMP1MMP12 | |
| SCHEMBL11739403 | 0.85 | PRKCA (0.58) | PRKCAPRKCDMAOBMMP1MMP12 | |
| SCHEMBL23049789 | 0.84 | PRKCA (0.60) | PRKCAPRKCDMAOBMMP1MMP12 | |
| SCHEMBL6310724 | 0.84 | PRKCA (0.60) | PRKCAPRKCDMAOBMMP1MMP12 | |
| SCHEMBL8789673 | 0.84 | ALOX5 (0.56) | PRKCAPRKCDMAOBMMP1MMP12 | |
| SCHEMBL27925866 | 0.84 | PRKCA (0.60) | PRKCAPRKCDMAOBMMP1MMP12 | |
| SCHEMBL9405203 | 0.84 | PRKCA (0.63) | PRKCAPRKCDMAOBMMP1MMP12 | |
| SCHEMBL27854715 | 0.84 | PRKCA (0.63) | PRKCAPRKCDMAOBMMP1MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295373-B | Compositions and methods for treating brain injury | 阿泽凡药物公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-102656168-B | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS INC | 2015-04-01 | — | — | CN | disclosed |
| CN-102770415-B | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS INC | 2014-09-24 | — | — | CN | disclosed |
| CN-102770415-A | Polycyclic compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS INC | 2012-11-07 | — | — | CN | disclosed |
| CN-1852712-B | Dual NK1/NK3 antagonists for treating schizophrenia | HOFFMANN LA ROCHE | 2010-06-09 | — | — | CN | disclosed |
| CN-101448844-A | Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists | HOFFMANN LA ROCHE (CH) | 2009-06-03 | — | — | CN | disclosed |
| CN-101374813-A | Arylsulfonamide and sulfonyl compounds as PPAR modulators and methods of treating metabolic disorders | KALYPSYS INC (US) | 2009-02-25 | — | — | CN | disclosed |
| EP-1385508-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2008-05-21 | — | — | EP | disclosed |
| CN-1852712-A | Dual NK1/NK3 antagonists for treating schizophrenia | HOFFMANN LA ROCHE (CH) | 2006-10-25 | — | — | CN | disclosed |
| US-20040097557-A1 | Cyanothiophene derivatives, compositions containing such compounds and methods of use | DUFFY JOSEPH L (US) | 2004-05-20 | — | — | US | disclosed |
| US-4328355-A | ANTIFERTILITY AGENTS | G. D. SEARLE & CO. (US) | 1982-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097557-A1 | Cyanothiophene derivatives, compositions containing such compounds and methods of use | GLP1R, GPR119, GCGR | PRKCA 2083/4885PRKCD 2650/4885MAOB 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.